Larimar Therapeutics (LRMR) Competitors $3.13 +0.25 (+8.75%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. CRON, XERS, PHAR, REPL, VIR, GYRE, PHAT, NUVB, DNA, and DAWNShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Cronos Group (CRON), Xeris Biopharma (XERS), Pharming Group (PHAR), Replimune Group (REPL), Vir Biotechnology (VIR), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Nuvation Bio (NUVB), Ginkgo Bioworks (DNA), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Cronos Group Xeris Biopharma Pharming Group Replimune Group Vir Biotechnology Gyre Therapeutics Phathom Pharmaceuticals Nuvation Bio Ginkgo Bioworks Day One Biopharmaceuticals Cronos Group (NASDAQ:CRON) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Is CRON or LRMR more profitable? Cronos Group has a net margin of 39.69% compared to Larimar Therapeutics' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group39.69% -0.07% -0.07% Larimar Therapeutics N/A -52.48%-46.08% Which has more volatility & risk, CRON or LRMR? Cronos Group has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CRON or LRMR? 8.7% of Cronos Group shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 7.3% of Cronos Group shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to CRON or LRMR? In the previous week, Larimar Therapeutics had 17 more articles in the media than Cronos Group. MarketBeat recorded 20 mentions for Larimar Therapeutics and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.79 beat Larimar Therapeutics' score of 0.76 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, CRON or LRMR? Cronos Group has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$124.59M6.18$41.08M$0.1315.35Larimar TherapeuticsN/AN/A-$80.60M-$1.49-2.10 Do analysts prefer CRON or LRMR? Larimar Therapeutics has a consensus target price of $18.50, indicating a potential upside of 490.68%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryCronos Group beats Larimar Therapeutics on 10 of the 16 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.81M$2.42B$5.50B$8.93BDividend YieldN/A1.79%5.38%4.12%P/E Ratio-2.088.9426.2519.86Price / SalesN/A665.31415.14113.78Price / CashN/A154.3736.4957.06Price / Book1.164.548.055.38Net Income-$80.60M$31.16M$3.16B$248.50M7 Day Performance-3.63%0.15%1.78%2.78%1 Month Performance42.36%8.74%4.74%5.84%1 Year Performance-59.38%2.17%35.81%20.06% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics1.8852 of 5 stars$3.13+8.8%$18.50+490.7%-65.0%$198.81MN/A-2.0830CRONCronos Group2.552 of 5 stars$1.91+0.5%N/A-16.5%$736.65M$117.61M14.69450XERSXeris Biopharma4.0977 of 5 stars$4.67-0.6%$6.25+33.8%+114.7%$730.30M$203.07M-15.57290Positive NewsPHARPharming Group2.9108 of 5 stars$10.68-2.9%$30.00+181.0%+30.4%$726.29M$297.20M-53.38280High Trading VolumeREPLReplimune Group3.9951 of 5 stars$9.29-0.4%$20.83+124.3%-2.2%$719.22MN/A-3.03210VIRVir Biotechnology3.4319 of 5 stars$5.04-2.5%$32.86+551.9%-43.8%$696.73M$74.21M-1.19580Positive NewsGYREGyre Therapeutics0.2919 of 5 stars$7.35-0.9%N/A-38.0%$689.14M$105.76M367.6840PHATPhathom Pharmaceuticals4.04 of 5 stars$9.59-1.5%$17.50+82.5%-18.1%$669.48M$55.25M-1.83110NUVBNuvation Bio3.4413 of 5 stars$1.96+1.3%$7.17+266.6%-38.7%$665.21M$7.87M-0.8360Gap UpHigh Trading VolumeDNAGinkgo Bioworks0.8177 of 5 stars$11.29+19.3%$5.77-48.9%N/A$660.80M$227.04M-1.23640DAWNDay One Biopharmaceuticals2.1324 of 5 stars$6.50+0.5%$30.57+370.3%-51.3%$658.84M$131.16M-9.1560Upcoming Earnings Related Companies and Tools Related Companies Cronos Group Alternatives Xeris Biopharma Alternatives Pharming Group Alternatives Replimune Group Alternatives Vir Biotechnology Alternatives Gyre Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Nuvation Bio Alternatives Ginkgo Bioworks Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
